Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
5,550 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04251533 | Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss(EPIK-B3) | terminated | Phase 3 | 137 | Novartis PharmaceuticalsINDUSTRY | 30 | Sep 10, 2026 | clinicaltrials |
| NCT04493853 | Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency(CAPItello-281) | active not recruiting | Phase 3 | 1,012 | AstraZenecaINDUSTRY |
| 32 |
| Sep 10, 2026 |
| clinicaltrials |
| NCT04931342 | A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors(BOUQUET) | active not recruiting | Phase 2 | 176 | Hoffmann-La RocheINDUSTRY | 13 | Sep 10, 2026 | clinicaltrials |
| NCT05111626 | Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.(FORTITUDE-102) | terminated | Phase 3 | 515 | AmgenINDUSTRY | 29 | Sep 10, 2026 | clinicaltrials |
| NCT05665595 | A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | terminated | Phase 3 | 1,594 | Merck Sharp & Dohme LLCINDUSTRY | 26 | Sep 10, 2026 | clinicaltrials |
| NCT05852691 | A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | active not recruiting | Phase 2 | 83 | Hoffmann-La RocheINDUSTRY | 16 | Sep 10, 2026 | clinicaltrials |
| NCT06106802 | Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment | recruiting | Phase 2 | 47 | Sehhoon ParkOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06687369 | A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | active not recruiting | Phase 3 | 726 | mAbxience Research S.L.INDUSTRY | 24 | Sep 10, 2026 | clinicaltrials |
| NCT06818643 | A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | recruiting | Phase 1 / Phase 2 | 270 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 10, 2026 | clinicaltrials |
| NCT07335497 | CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors(ASCEND) | recruiting | Phase 1 / Phase 2 | 290 | Crescent Biopharma, Inc.INDUSTRY | 8 | Sep 10, 2026 | clinicaltrials |
| NCT07812805 | SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors | recruiting | Phase 1 | 100 | SK Life Science, Inc.INDUSTRY | 2 | Sep 10, 2026 | clinicaltrials |
| NCT03040973 | Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone | active not recruiting | Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 9, 2026 | clinicaltrials |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma(EPCORE™ NHL-1) | active not recruiting | Phase 1 / Phase 2 | 666 | GenmabINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT04351555 | A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer(NeoADAURA) | active not recruiting | Phase 3 | 358 | AstraZenecaINDUSTRY | 25 | Sep 9, 2026 | clinicaltrials |
| NCT04590963 | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer(INTERLINK-1) | active not recruiting | Phase 3 | 370 | AstraZenecaINDUSTRY | 23 | Sep 9, 2026 | clinicaltrials |
| NCT05091567 | A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer(IMforte) | active not recruiting | Phase 3 | 660 | Hoffmann-La RocheINDUSTRY | 13 | Sep 9, 2026 | clinicaltrials |
| NCT05226871 | Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies | active not recruiting | Phase 2 | 35 | PfizerINDUSTRY | 7 | Sep 9, 2026 | clinicaltrials |
| NCT05361395 | First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) | active not recruiting | Phase 1 | 184 | AmgenINDUSTRY | 15 | Sep 9, 2026 | clinicaltrials |
| NCT05386108 | Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer(ELECTRA) | recruiting | Phase 1 / Phase 2 | 73 | Stemline Therapeutics, Inc.INDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT05968326 | A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC(IMCODE003) | active not recruiting | Phase 2 | 260 | Genentech, Inc.INDUSTRY | 10 | Sep 9, 2026 | clinicaltrials |
| NCT06253871 | A Phase 1/1b Study of IAM1363 in HER2 Cancers | recruiting | Phase 1 | 383 | Iambic Therapeutics, IncINDUSTRY | 8 | Sep 9, 2026 | clinicaltrials |
| NCT06421935 | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | active not recruiting | Phase 1 | 60 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 5 | Sep 9, 2026 | clinicaltrials |
| NCT06625775 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 392 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
| NCT06635824 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) | active not recruiting | Phase 3 | 191 | GenmabINDUSTRY | 27 | Sep 9, 2026 | clinicaltrials |
| NCT06780137 | A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | recruiting | Phase 1 / Phase 2 | 327 | Merck Sharp & Dohme LLCINDUSTRY | 12 | Sep 9, 2026 | clinicaltrials |
| NCT06927648 | CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA | recruiting | — | 130 | AstraZenecaINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07529717 | First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer(CRIUS-1) | recruiting | Phase 1 / Phase 2 | 42 | AstraZenecaINDUSTRY | 3 | Sep 9, 2026 | clinicaltrials |
| NCT07541170 | A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)(KRASCENDO 3) | recruiting | Phase 3 | 400 | Hoffmann-La RocheINDUSTRY | 6 | Sep 9, 2026 | clinicaltrials |
| NCT07549412 | A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | recruiting | Phase 3 | 1,020 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 16 | Sep 9, 2026 | clinicaltrials |
| NCT05091424 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | recruiting | Phase 1 | 332 | Hoffmann-La RocheINDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT05307705 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors(PIKASSO-01) | recruiting | Phase 1 | 260 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
| NCT05789082 | A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation(KRAScendo 170) | recruiting | Phase 1 / Phase 2 | 320 | Hoffmann-La RocheINDUSTRY | 18 | Sep 8, 2026 | clinicaltrials |
| NCT05800665 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Genentech, Inc.INDUSTRY | 7 | Sep 8, 2026 | clinicaltrials |
| NCT05801029 | A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations(OSTARA) | active not recruiting | Phase 2 | 60 | AstraZenecaINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06051162 | HPI Effect in Robotic Urological Surgery on AKI | completed | N/A | 124 | Ewha Womans University Mokdong HospitalOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer(SUNRAY-01) | recruiting | Phase 3 | 1,264 | Eli Lilly and CompanyINDUSTRY | 29 | Sep 8, 2026 | clinicaltrials |
| NCT06561685 | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 340 | Eli Lilly and CompanyINDUSTRY | 6 | Sep 8, 2026 | clinicaltrials |
| NCT06564038 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies(Soundtrack-E) | recruiting | Phase 1 / Phase 2 | 408 | AstraZenecaINDUSTRY | 13 | Sep 8, 2026 | clinicaltrials |
| NCT07005128 | A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)(DeLLphi-312) | active not recruiting | Phase 3 | 350 | AmgenINDUSTRY | 26 | Sep 8, 2026 | clinicaltrials |
| NCT07100106 | A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer(MoonROSE) | recruiting | Phase 1 / Phase 2 | 285 | Genentech, Inc.INDUSTRY | 10 | Sep 8, 2026 | clinicaltrials |
| NCT07405801 | A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer | recruiting | Phase 2 | 80 | Hoffmann-La RocheINDUSTRY | 12 | Sep 8, 2026 | clinicaltrials |
Data updated 21 days agoSource updated unknownsource: clinicaltrials